Literature DB >> 207518

Cyclic AMP-binding proteins: inverse relationship with estrogen-receptors in hormone-dependent mammary tumor regression.

Y S Cho-Chung, J S Bodwin, T Clair.   

Abstract

Dimethylbenzanthracene-induced rat carcinomas possess activities binding cyclic adenosine 3':5'-monophosphate (cAMP) and estrogen. When dimethylbenzanthracene-induced tumors regress after ovariectomy of the host, a change in the specific binding of cAMP and estrogen occurs in the tumors. Six days after ovariectomy, cAMP binding increases 5-fold in the nuclei and 2-fold in the cytosol of tumors, while nuclear and cytoplasmic estrogen binding decreases by 80% and 50%, respectively. These changes in activities binding cAMP and estrogen are detectable within 1 day after ovariectomy and the changes are reversed when resumption of tumor growth is induced by the injection of 17beta-estradiol. When dimethylbenzanthracene-induced tumors fail to regress after ovariectomy, the change in activities binding cAMP and estrogen does not occur. Significant increases in the cAMP level as well as in adenylate cyclase and cAMP-phosphodiesterase activities are also found in the regressing tumors. Concomitant with the increase of cAMP-binding activity is an increase in histone kinase activity in the regressing tumor. These data suggest the involvement of cAMP in the growth control of a hormone-dependent mammary rumor.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 207518     DOI: 10.1111/j.1432-1033.1978.tb12283.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  11 in total

1.  Cyclic nucleotide levels in human breast cancer and in rat mammary tissues during tumor development.

Authors:  E Israeli; B Raz; H Kerner; D Barzilai
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

2.  3,4-bis(3'-hydroxyphenyl)hexane--a new mammary tumor-inhibiting compound. Studies on the mechanism of action on the DMBA-induced, hormone-dependent mammary tumor of the rat.

Authors:  R W Hartmann; H Schönenberger; K H Wrobel
Journal:  J Cancer Res Clin Oncol       Date:  1982       Impact factor: 4.553

3.  Selective modulation of protein kinase isozymes by the site-selective analog 8-chloroadenosine 3',5'-cyclic monophosphate provides a biological means for control of human colon cancer cell growth.

Authors:  S Ally; G Tortora; T Clair; D Grieco; G Merlo; D Katsaros; D Ogreid; S O Døskeland; T Jahnsen; Y S Cho-Chung
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

4.  Relationship of cyclic AMP binding capacity and estrogen receptor to hormone sensitivity in human breast cancer.

Authors:  S Kvinnsland; R Ekanger; S O Døskeland; T Thorsen
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

5.  Tumour cyclic AMP binding proteins and endocrine responsiveness in patients with inoperable breast cancer.

Authors:  D M Watson; R A Hawkins; N J Bundred; H J Stewart; W R Miller
Journal:  Br J Cancer       Date:  1987-08       Impact factor: 7.640

6.  Variations in steroid receptors and cyclic AMP binding proteins across human breast cancers: evidence for heterogeneity.

Authors:  R O Senbanjo; W R Miller; R A Hawkins
Journal:  Br J Cancer       Date:  1986-07       Impact factor: 7.640

7.  Prospective evaluation of prognostic factors in operable breast cancer.

Authors:  R A Hawkins; A L Tesdale; M E Killen; W J Jack; U Chetty; J M Dixon; M J Hulme; R J Prescott; M A McIntyre; W R Miller
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

8.  Cyclic adenosine 3',5'-monophosphate-binding proteins in human ovarian cancers.

Authors:  A D Ramage; D J Burns; W R Miller
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

9.  Does the oestrogen receptor concentration of a breast cancer change during systemic therapy?

Authors:  R A Hawkins; A L Tesdale; E D Anderson; P A Levack; U Chetty; A P Forrest
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

10.  Cyclic AMP binding proteins in human breast cancer.

Authors:  W R Miller; R O Senbanjo; J Telford; D M Watson
Journal:  Br J Cancer       Date:  1985-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.